Alliance Pharma’s (LON:APH) interim results will meet expectations with sales of Hydromol and Ashton & Parsons infant powder remaining strong.
The group, which acquires mature prescription treatments no longer wanted by major pharmas, said total revenues for the six months to June were approximately £22.5mln (£22.8mln) or £21.4mln (£22.8mln) stripping out joint venture income.
Sales of eczema cream Hydromol rose 15% to £3mln in the period, while Ashton & Parsons sales were £0.7mln compared to £0.1 mln a year ago when production capacity was an issue.
Nu-Seals revenue declined slightly to £1.4mln (2013: £1.6mln), while recent acquisitions Lypsyl in the UK and Ireland and Irenat in Germany generated £0.5 mln and £0.4 mln respectively.
Alliance said: “We continue to expect trading performance in 2014 to be in line with our plans, before the positive impact of any further acquisitions.
“Around £22 mln of our acquisition bank facility remains undrawn and available to fund opportunities as they arise.”